42B7A295-5E3D-44DA-B93F-40E64A551364
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 62.91064388961892
- age_years
- 33
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.530
- ALLOGRAFT_REJECTION+0.473
- IL6_JAK_STAT3_SIGNALING+0.456
- TGF_BETA_SIGNALING+0.455
- MYC_TARGETS_V2+0.452
- UNFOLDED_PROTEIN_RESPONSE+0.438
- TNFA_SIGNALING_VIA_NFKB+0.414
- INTERFERON_GAMMA_RESPONSE+0.411
- MYC_TARGETS_V1+0.378
- ANGIOGENESIS+0.374
Top 10 suppressed
- KRAS_SIGNALING_DN-0.464
- PANCREAS_BETA_CELLS-0.454
- SPERMATOGENESIS-0.367
- MYOGENESIS-0.267
- OXIDATIVE_PHOSPHORYLATION-0.120
- APICAL_SURFACE-0.119
- HEDGEHOG_SIGNALING-0.092
- XENOBIOTIC_METABOLISM-0.069
- ESTROGEN_RESPONSE_LATE-0.053
- BILE_ACID_METABOLISM-0.036
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934875 | — | — | 0.946 |
| 2 | SRR934942 | — | — | 0.945 |
| 3 | SRR934936 | — | — | 0.945 |
| 4 | SRR934895 | — | — | 0.936 |
| 5 | SRR934961 | — | — | 0.932 |
| 6 | 6CAD21AA-CB33-402E-B64C-685F576B7653 | — | — | 0.929 |
| 7 | SRR934934 | — | — | 0.929 |
| 8 | SRR934753 | — | — | 0.929 |
| 9 | 62966348-1C16-4A6D-AA82-707B3F759D5C | — | — | 0.927 |
| 10 | SRR934926 | — | — | 0.927 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 39 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.530 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.473 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.456 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.455 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.452 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.438 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.414 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.411 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.378 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.374 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.365 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.352 | Idelalisib | — uncovered |
| APOPTOSIS | 0.350 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.344 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.340 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.326 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.326 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.313 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.305 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.301 | Inavolisib | — uncovered |